Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment
Launched by CHULALONGKORN UNIVERSITY · Feb 1, 2011
Trial Information
Current as of May 22, 2025
Terminated
Keywords
ClinConnect Summary
Recombinant human erythropoietin was the first biotherapeutic medicinal product derived from recombinant DNA technology for the treatment of anemia in patients with chronic kidney disease (CKD). Although r-HuEpo raises hemoglobin levels in CKD and improves morbidity associated with anemia in CKD patients, the adverse immunological effect of r-HuEpo administered subcutaneously can result in anti-r-HuEpo associated PRCA. We aim to evaluate the effectiveness of two treatment protocol, cyclosporine combined with mycophenolate mofetil and cyclophosphamide combined with prednisolone for treatment...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age more than 18 years old
- • CKD patient with anti-r-huEpo associated PRCA
- Exclusion Criteria:
- • Pregnancy or lactating women
- • Receiving immunosuppression
- • Active infection
- • Previous history of allergic reaction to cyclosporine, mycophenolate mofetil, cyclophosphamide, prednisolone
About Chulalongkorn University
Chulalongkorn University, one of Thailand's premier academic institutions, is dedicated to advancing medical research and enhancing healthcare outcomes through innovative clinical trials. With a strong emphasis on collaboration and interdisciplinary approaches, the university leverages its extensive resources and expertise in various medical fields to conduct rigorous scientific investigations. Chulalongkorn University aims to contribute to global health advancements by fostering a culture of excellence in research, education, and community service, ultimately improving patient care and public health standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bangkok, , Thailand
Patients applied
Trial Officials
Kearkiat Praditpornsilpa, MD
Principal Investigator
Chulalongkorn University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials